Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation
Open Access
- 5 July 2011
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 4 (7) , 992-1018
Abstract
The amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is widely abused as a recreational drug due to its unique psychological effects. Of interest, MDMA causes long-lasting deficits in neurochemical and histological markers of the serotonergic neurons in the brain of different animal species. Such deficits include the decline in the activity of tryptophan hydroxylase in parallel with the loss of 5-HT and its main metabolite 5-hydoxyindoleacetic acid (5-HIAA) along with a lower binding of specific ligands to the 5-HT transporters (SERT). Of concern, reduced 5-HIAA levels in the CSF and SERT density have also been reported in human ecstasy users, what has been interpreted to reflect the loss of serotonergic fibers and terminals. The neurotoxic potential of MDMA has been questioned in recent years based on studies that failed to show the loss of the SERT protein by western blot or the lack of reactive astrogliosis after MDMA exposure. In addition, MDMA produces a long-lasting down-regulation of SERT gene expression; which, on the whole, has been used to invoke neuromodulatory mechanisms as an explanation to MDMA-induced 5-HT deficits. While decreased protein levels do not necessarily reflect neurodegeneration, the opposite is also true, that is, neuroregulatory mechanisms do not preclude the existence of 5-HT terminal degeneration.Keywords
This publication has 198 references indexed in Scilit:
- MDMA (“ecstasy”) abuse as an example of dopamine neuroplasticityNeuroscience & Biobehavioral Reviews, 2011
- MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning.Behavioral Neuroscience, 2009
- Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brainBrain Research, 2009
- Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brainNeuroscience, 2009
- Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: Mitochondrial targeted preconditioningAdvanced Drug Delivery Reviews, 2008
- Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neuronsPharmacology Biochemistry and Behavior, 2008
- Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performancePsychopharmacology, 2008
- 3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleusNeuroscience, 2008
- The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brainNeuroscience, 2007
- Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophanLife Sciences, 1994